The Financial Post reports in its Saturday edition that Michael Carr, a 68-year-old investment banker at Goldman Sachs, passed away on May 12 at Mount Sinai Hospital in Manhattan. A Bloomberg dispatch to the Post reports that Mr. Carr had recently been diagnosed with a neurodegenerative disease and faced complications. Mr. Carr joined Goldman as a partner in 1998, a year before the firm went public. He rose to help lead the bank's mergers and acquisitions division through the deal-making boom in the wake of the COVID-19 pandemic. He retired as a partner in 2022 and worked as an advisory director through 2024. Chief executive officer David Solomon said in a memo: "A number of us have had the privilege of getting to know and working closely with Michael over the course of many years. Not only was Michael an outstanding leader at the firm and in our investment banking business, he was also incredibly kind to everyone he crossed paths with and immensely generous." Mr. Carr became global co-head of mergers and acquisitions in 2015. Throughout the years, his team worked on some of the largest deals, including CVS Health's $70-billion (U.S.) purchase of health insurer Aetna and Abbvi's $63-billion (U.S.) purchase of Allergan.